TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAntalya Training and Research Hospital
About this trial
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.
Eligibility criteria
Qualifiers
Signed informed consent form.
Diagnosis of stage IV non-small cell lung cancer.
Male or female patients aged 18 years or older.
Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye.
Disqualifiers
Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication.
Known or suspected hypersensitivity to atezolizumab.
Pregnant or breastfeeding women.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
150 Participants
are grouped into 1 trial groupSponsors and collaborators
Antalya Training and Research Hospital
Lead sponsor
Hoffmann-La Roche
Collaborator
Source ClinicalTrials.gov